Mattes Hollnagel

Mr. Mattes Hollnagel


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2025 in Molecules
Verified
Journal Article
Open access
PDF file
MAMalte Arnold
Malte Arnold
TTTemi Thompson
Temi Thompson
LGLorraine Glennie
Lorraine Glennie
MHMattes Hollnagel
Mattes Hollnagel
GSGopal Sapkota
Gopal Sapkota
CPChristian Peifer
Christian Peifer
The dysregulation of CK1 isoforms is linked to various types of diseases, including neurodegeneration and different types of neoplasia such as colon, pancreatic, breast, and ovarian cancer. For CK1 isoforms, a plethora of effective small molecule inhibitors are available. However, only a few degraders of CK1α and, more recently, proteolysis targeting chimeras (PROTACs) for CK1δ/CK1ε have been reported. In this study, we applied the PROTAC concept by harnessing molecular modelling to design and synthesize a series of candidate CK1δ-targeting PROTACs based on a highly specific and potent benzothiazole-based CK1δ inhibitor that we previously developed in our lab. In the present study, we established a modular synthetic platform to systematically generate a set of PROTAC degrader candidates consisting of the CK1δ-specific inhibitor scaffold, alkyl and PEG linker motifs with various lengths, and Cereblon (CRBN)-engaging pomalidomide and thalidomide derivatives as E3 ligase binders. We demonstrate that several PROTACs degrade CK1δ/ε in various cells. The most potent PROTAC P1d inhibits the phosphorylation of downstream substrates through CK1δ/ε degradation. We establish the requirement of CUL4ACRBN and the proteasome for the P1d-mediated degradation of CK1δ/ε.

31 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MAMalte Arnold
Malte Arnold
TTTemi Thompson
Temi Thompson
LGLorraine Glennie
Lorraine Glennie
MHMattes Hollnagel
Mattes Hollnagel
GSGopal Sapkota
Gopal Sapkota
CPChristian Peifer
Christian Peifer
Dysregulation of CK1 isoforms is linked to various types of diseases, including neuro-degeneration and different types of neoplasia such as colon-, pancreatic-, breast-, and ovarian cancer. For CK1 isoforms, a plethora of effective small molecule inhibitors are available. However, only a few degraders of CK1α and, more recently, PROteolysis TArgeting Chimeras (PROTACs) for CK1δ/CK1ε have been reported. In this study, we applied the PROTAC concept by harnessing molecular modeling to design and synthe-size a series of candidate CK1δ-targeting PROTACs based on a highly specific and po-tent benzothiazole-based CK1δ-inhibitor that we previously developed in our lab. In the present study, we established a modular synthetic platform to systematically gen-erate a set of PROTAC degrader candidates consisting of the CK1δ-specific inhibitor scaffold, alkyl- and PEG-linker motifs with various lengths, and Cereblon (CRBN)-engaging pomalidomide and thalidomide derivatives as E3 ligase binders. We demonstrate that several PROTACs degrade CK1δ/ε in various cells. The most potent PROTAC P1d inhibits the phosphorylation of downstream substrates through CK1δ/ε degradation. We establish the requirement of CUL4ACRBN and the proteasome for P1d-mediated degradation of CK1δ/ε.